Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 207

  • Unknown sort schema '{last_sort_schema}' ignored
1.

Burnout and Resiliency Among Family Medicine Program Directors.

Porter M, Hagan H, Klassen R, Yang Y, Seehusen DA, Carek PJ.

Fam Med. 2018 Feb;50(2):106-112. doi: 10.22454/FamMed.2018.836595.

2.

Patterns and Gaps Identified in a Systematic Review of the Hepatitis C Virus Care Continuum in Studies among People Who Use Drugs.

Jordan AE, Perlman DC, Reed J, Smith DJ, Hagan H.

Front Public Health. 2017 Dec 18;5:348. doi: 10.3389/fpubh.2017.00348. eCollection 2017.

3.

Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis.

Jordan AE, Perlman DC, Smith DJ, Reed JR, Hagan H.

J Clin Epidemiol. 2018 Jan;93:66-75. doi: 10.1016/j.jclinepi.2017.10.015. Epub 2017 Nov 2.

PMID:
29102682
4.

Epidemiology of Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis.

Smith DJ, Neurer J, Jordan AE, Hagan H.

JMIR Res Protoc. 2017 Oct 20;6(10):e201. doi: 10.2196/resprot.7936.

5.

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M.

Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021. doi: 10.1002/14651858.CD012021.pub2. Review.

6.

Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M.

Addiction. 2018 Mar;113(3):545-563. doi: 10.1111/add.14012. Epub 2017 Oct 23. Review.

7.

Trends in HIV and HCV Risk Behaviors and Prevalent Infection Among People Who Inject Drugs in New York City, 2005-2012.

Neaigus A, Reilly KH, Jenness SM, Hagan H, Wendel T, Gelpi-Acosta C, Marshall DM 4th.

J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S325-S332. doi: 10.1097/QAI.0000000000001407.

PMID:
28604434
8.

Past-year prevalence of prescription opioid misuse among those 11 to 30years of age in the United States: A systematic review and meta-analysis.

Jordan AE, Blackburn NA, Des Jarlais DC, Hagan H.

J Subst Abuse Treat. 2017 Jun;77:31-37. doi: 10.1016/j.jsat.2017.03.007. Epub 2017 Mar 12. Review.

PMID:
28476268
9.

Continuing Links Between Substance Use and HIV Highlight the Importance of Nursing Roles.

Deren S, Naegle M, Hagan H, Ompad DC.

J Assoc Nurses AIDS Care. 2017 Jul - Aug;28(4):622-632. doi: 10.1016/j.jana.2017.03.005. Epub 2017 Mar 24.

PMID:
28456473
10.

Public Health Benefit of Peer-Referral Strategies for Detecting Undiagnosed HIV Infection Among High-Risk Heterosexuals in New York City.

Gwadz M, Cleland CM, Perlman DC, Hagan H, Jenness SM, Leonard NR, Ritchie AS, Kutnick A.

J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):499-507. doi: 10.1097/QAI.0000000000001257.

11.

Check Hep C: A Community-Based Approach to Hepatitis C Diagnosis and Linkage to Care in High-Risk Populations.

Ford MM, Jordan AE, Johnson N, Rude E, Laraque F, Varma JK, Hagan H.

J Public Health Manag Pract. 2018 Jan/Feb;24(1):41-48. doi: 10.1097/PHH.0000000000000519.

PMID:
28141668
12.

Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus.

Des Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Tross S, Perlman DC, Campbell AN, Hagan H, Cooper HL.

Sex Transm Dis. 2017 Feb;44(2):85-90. doi: 10.1097/OLQ.0000000000000549.

13.

From Long-Term Injecting to Long-Term Non-Injecting Heroin and Cocaine Use: The Persistence of Changed Drug Habits.

Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Barnes DM, Tross S, Perlman DC, Campbell AN, Cooper HL, Hagan H.

J Subst Abuse Treat. 2016 Dec;71:48-53. doi: 10.1016/j.jsat.2016.08.015. Epub 2016 Aug 21.

14.

Explaining Racial/Ethnic Dietary Patterns in Relation to Type 2 Diabetes: An Analysis of NHANES 2007-2012.

Nowlin SY, Cleland CM, Vadiveloo M, D'Eramo Melkus G, Parekh N, Hagan H.

Ethn Dis. 2016 Oct 20;26(4):529-536.

15.

The Interaction of Risk Network Structures and Virus Natural History in the Non-spreading of HIV Among People Who Inject Drugs in the Early Stages of the Epidemic.

Dombrowski K, Khan B, Habecker P, Hagan H, Friedman SR, Saad M.

AIDS Behav. 2017 Apr;21(4):1004-1015. doi: 10.1007/s10461-016-1568-6.

16.

What happened to the HIV epidemic among non-injecting drug users in New York City?

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Campbell AN, Tross S, Cooper HL, Hagan H, Perlman DC.

Addiction. 2017 Feb;112(2):290-298. doi: 10.1111/add.13601. Epub 2016 Nov 14.

18.

The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis.

Reed JR, Jordan AE, Perlman DC, Smith DJ, Hagan H.

Syst Rev. 2016 Jul 11;5(1):110. doi: 10.1186/s13643-016-0293-6. Review.

19.

Response to the calculation of population attributable fractions of risk factors for hepatitis C transmission: authors' reply.

Hagan H, Jordan AE, Cleland CM.

AIDS. 2016 Jun 19;30(10):1685. doi: 10.1097/QAD.0000000000001091. No abstract available.

PMID:
27243778
20.

Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs.

Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Hickman M.

Cochrane Database Syst Rev. 2016;2016(1). pii: CD012021. Epub 2016 Jan 12. Update in: Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021.

Supplemental Content

Support Center